FICHIT

Je m'inscris

CERENIS THERAPEUTICS

0/5 (0 note(s))
Note donnée : aucune
Paris
185
Cerenis Therapeutics is an international biopharmaceutical company dedicated to the discovery and development of innovative HDL therapies for the treatment of cardiovascular and metabolic diseases.
CER-001 is an engineered complex of recombinant human apoA-I, the major structural protein of HDL, and phospholipids. It has been designed to mimic the structure and function of natural, nascent HDL, also known as pre-beta HDL. Its mechanism of action is to increase apoA-I and the number of HDL particles transiently, to stimulate the removal of excess cholesterol and other lipids from tissues including the arterial wall and to transport them to the liver for elimination through a process called Reverse Lipid Transport.
CER-001 is currently included in two clinical studies for two indications: CARAT, a phase II trial in post Acute Coronary Syndrome (ACS) and TANGO, a phase III trial in patients with HDL genetic defects (suffering from ApoA-I and ABCA1 deficiency, indications which are part of FPHA*disorders)
TUPIN Cyrille
www.cerenis.com
CEREN:FP

Fiche créée le 10/04/2016 par Guillaume   vue 9 fois.